Premium
Expression of membrane type 1 matrix metalloproteinase in medullary thyroid carcinoma: Prognostic implications
Author(s) -
Cavalheiro Beatriz Godoi,
Junqueira Consuelo Rodrigues,
Brandão Lenine Garcia
Publication year - 2010
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.21146
Subject(s) - immunostaining , medullary cavity , medicine , thyroid carcinoma , medullary carcinoma , matrix metalloproteinase , pathology , matrix metalloproteinase 9 , stage (stratigraphy) , thyroid , carcinoma , immunohistochemistry , metalloproteinase , oncology , biology , paleontology
Background. Clinical and pathologic examinations cannot always provide a prognosis for patients with medullary thyroid carcinoma. Membrane type 1 matrix metalloproteinase (MT1‐MMP) can act directly on carcinogenesis and takes part in 1 of the processes of metalloproteinase 2 activation, an enzyme related to prognostic impairment of patients with such tumor. Methods. Thirty‐five patients who were submitted to surgery were followed up for an average of 74 months. Postoperative and final medical conditions were characterized for comparison with MT1‐MMP immunostainings, performed in surgical paraffin blocks. A value of p < .05 was considered statistically significant. Results. Proposed index (association of proportion and intensity of immunostaining) and proportion of immunostained cells in primary specimens were correlated with cure or persistence after initial operations ( p = .0216 and p = .0098, respectively). Conclusion. MT1‐MMP immunostaining in primary tumor specimens is a new and complementary prognostic predictor in patients with medullary thyroid carcinomas. © 2009 Wiley Periodicals, Inc. Head Neck, 2010